AIRNA, a biotech startup specializing in RNA editing therapies, has successfully closed an oversubscribed $60 million Series A financing round. The funding round was led by German venture capital firm Forbion. AIRNA's lead program focuses on addressing Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can affect the liver or lungs and lead to chronic obstructive pulmonary disease. Investors are optimistic about AIRNA's approach, particularly in light of upcoming clinical readouts from other companies in the field, such as Wave Life Sciences.